Image source: Getty Images
Telix Pharmaceuticals vs Clinuvel Pharmaceuticals shares
If you're thinking about putting $1,000 into an ASX healthcare stock, Telix Pharmaceuticals Ltd (ASX: TLX) and Clinuvel Pharmaceuticals Ltd (ASX: CUV) are likely on your radar. Both are pioneering companies in Australian biotech with global ambitions, but they have some stark differences. Let's weigh up Telix Pharmaceuticals vs Clinuvel Pharmaceuticals shares to see which one might suit an investor chasing growth, value, or something in between.
The case for Telix Pharmaceuticals
Telix Pharmaceuticals is a commercial-stage biopharma player focused on developing and selling theranostic (both diagnostic and therapeutic) products using targeted radiation. Its key product, Illuccix, is approved for prostate cancer imaging in Australia, the US, and Canada, and the company is pushing for approvals in Europe and the UK. Beyond this, it's running over 20 clinical trials globally across major cancer types including prostate, kidney, brain, and bone marrow conditions. Telix is headquartered in Australia but operates on several continents.
Three stand-out points about Telix from the data:
- It's much larger than Clinuvel, with a market cap of $5.40 billion.
- Year to date, its shares are up an impressive 37.6%.
- The company sports a very high price-to-earnings (P/E) ratio of 108.53, reflecting high investor hopes for future growth rather than current earnings.
It's worth noting that Telix does not pay a dividend, so investors here are backing future growth rather than income.
The case for Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is best known for its drug SCENESSE, which helps people with rare genetic disorders causing extreme intolerance to sunlight. Clinuvel focuses on innovative treatments for both genetic and vascular skin disorders, and earns most of its revenue from the US and Europe. Like Telix, it's an Australian company with an international outlook.
Highlights for Clinuvel from the figures:
- It is much smaller in scale than Telix, with a market cap of $413.5 million.
- The company's P/E ratio stands at 12.17, considerably lower than Telix's, indicating the shares are valued far closer to current earnings.
- Dividend-wise, Clinuvel pays a fully franked yield of 0.62%, recently delivering annual dividends of 5 cents per share, all fully franked, which is a rare treat among Aussie biotechs.
However, Clinuvel shares have dropped 34.4% year to date, reflecting a tough patch for the business or perhaps shifts in investor expectations.
Valuation comparison
Here's how the two stack up on main valuation and yield measures:
| Metric | Telix Pharmaceuticals | Clinuvel Pharmaceuticals |
|---|---|---|
| Market Cap | $5.40 billion | $413.51 million |
| P/E Ratio | 108.53 | 12.17 |
| Earnings per Share (EPS) | $0.099 | $0.668 |
| Dividend Yield | 0.00% | 0.62% (fully franked) |
| Dividend per Share | N/A | $0.05 |
Note: Clinuvel's reported P/E and EPS are consistent, while Telix's very high P/E reflects its current tiny but positive earnings. Telix does not pay dividends, whereas Clinuvel does, with a fully franked yield.
Recent share price momentum
Comparing recent share price performance up to 7 October 2026:
- Telix Pharmaceuticals closed at $15.87 on 7 October 2026, with a year-to-date return of 37.6%.
- Clinuvel Pharmaceuticals closed at $8.20 on 7 October 2026, with a year-to-date return of -34.4%.
- Over the previous trading week, Telix shares jumped 2.99% on the most recent day, and showed strong overall momentum despite some volatile days.
- Clinuvel shares, in contrast, edged up 0.86% on the same day, but have been trending down for most of the year.
Which is the better buy?
If I was picking between Telix Pharmaceuticals and Clinuvel Pharmaceuticals to invest $1,000 right now, I'd lean toward Telix. The company is much larger, more diversified across major cancer indications, and has clear momentum both in its operational progress and in the share price this year. While Telix is definitely priced for optimism with a sky-high P/E multiple (108.53), its strong pipeline and global approvals for Illuccix are impressive.
Clinuvel does stand out for paying a fully franked dividend—very rare among Australian biotechs—and the shares trade at a far lower P/E ratio (12.17), which could appeal to value-seekers. Yet, the steep year-to-date drop in the share price raises questions. Unless I was after income above all else or felt confident in a turnaround, I'd be more comfortable backing Telix's proven momentum and future-facing pipeline in the current landscape.
